On Monday, Shares of Tesla Motors Inc (NASDAQ:TSLA), added 4.74% and closed at $213.70 in the last trading session. The last trading range of the stock ranges between $208.25 and $215.67. Tesla ( NASDAQ : TSLA ) delivered about 24,500 vehicles in Q3, of which 15,800 were Model S and 8,700 were Model X. This was a boost of just over 70% from last quarter’s deliveries of 14,402. Our Q3 delivery count should be viewed as slightly conservative, as we only count a car as delivered if it is transferred to the customer and all paperwork is correct.
In addition to Q3 deliveries, about 5,500 vehicles were in transit to customers at the end of the quarter. These will not be counted as deliveries until Q4.
Production rose to 25,185 vehicles in Q3. This was a boost of 37% from Q2 production of 18,345.
We expect Q4 deliveries and production to be at or slightly above Q3, despite Q4 being a shorter quarter and the challenge of delivering vehicles in winter weather over holidays. Guidance of 50,000 vehicles for the second half of 2016 is maintained.
Finally, we note that starting in Q3, our quarterly financial releases will no longer include non-GAAP revenue and related financial metrics resulting from vehicles leased through our banking partners or that include resale value guarantees. We will, however, continue to provide additional supplemental information to shareholders to provide insights into our business.
Tesla vehicle deliveries represent only one measure of the company’s financial performance and should not be relied on as an indicator of quarterly financial results, which depend on various factors, counting the cost of sales, foreign exchange movements and mix of directly leased vehicles.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), jumped 6.95% and closed at $6.77 in the last trading session. The last trading range of the stock ranges between $6.30 and $6.84. The company’s Market capitalization is $524.33 million with the total Outstanding Shares of 69.99 million. Progenics Pharmaceuticals, Inc. develops medicines for oncology in the United States and internationally. The companys primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule that has accomplished Phase II testing, in addition to acts as an imaging agent to diagnose and detect prostate cancer; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted PET imaging agent for prostate cancer. Its clinical-stage product candidates also comprise 1095, a PSMA-targeted Iodine-131 labeled small radiopharmaceutical molecule for the treatment of metastatic castration resistant prostate cancer; PSMA antibody-drug conjugate, which has accomplished Phase II testing in chemotherapy-practiced patients and is ongoing second cohort in chemotherapy-naïve patients for the treatment of prostate cancer; and EXINI Bone BSI, an analytical tool for analysis of bone scan index from bone scintigraphy images. The company also offers Relistor-subcutaneous injection for the treatment of opioid induced constipation (OIC) in advanced-illness patients receiving palliative care when laxative therapy has not been sufficient; and for treatment of OIC inpatients with non-cancer pain. In addition, it develops Relistor-oral that has accomplished Phase III testing for the treatment of OIC; and PRO 140, which is in Phase III testing for HIV treatment. The company has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and with Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA, in addition to has partnershipagreement with Seattle Genetics, Inc.
Honda Motor Co Ltd (ADR)(NYSE:HMC), gained 0.31% and closed at $29.01 in the last trading session. The last trading range of the stock ranges between $28.90 and $29.12. During the 52-week trading session the minimum price at which share price traded, registered at $24.03 and reached to max level of $33.87. Honda Motor Co., Ltd. develops, manufactures, and distributes motorcycles, automobiles, power products, and other products worldwide. The company operates through four segments: Motorcycle Business, Automobile Business, Financial Services Business, and Power Product and Other Businesses. The Motorcycle Business segment produces sports models, counting trial and moto-cross racing vehicles; business and commuter models; all-terrain vehicles; and side-by-side models. The Automobile Business segment offers passenger cars, light trucks, and mini vehicles, in addition to vehicles powered with alternative fuel, such as ethanol, battery electric and fuel cell vehicles. The Financial Services Business segment provides various financial services, counting retail lending, leasing, and other financial services comprising wholesale financing to dealers and customers. The Power Product and Other Businesses segment engages in the manufacture and sale of various power products consisting of general-purpose engines, generators, water pumps, lawn mowers, riding mowers, grass cutters, brush cutters, tillers, snow blowers, outboard marine engines, power carriers, sprayers, pressure washers, and cogeneration units. This segment also offers HondaJet aircraft.